SU2C-MARK Lung Cancer Consortium - Checkpoint Blockade Response Project
Demographics (5)
- HARMONIZED_OS_DAYS - Overall survival (OS) in days (phv00504466.v1.p1)
- HARMONIZED_PFS_DAYS - Progression-free survival (PFS) in days (phv00504462.v1.p1)
- PATIENT_AGE_AT_DIAGNOSIS - Patient age at cancer diagnosis (phv00504441.v1.p1)
- PATIENT_SEX - Patient sex (phv00504442.v1.p1)
- SEX - Biological sex (phv00504426.v1.p1)
Disease Events (12)
- CLINICAL_DRIVER - Clinical driver identified by targeted sequencing (phv00504453.v1.p1)
- HARMONIZED_BOR_RECIST - RECISTv1.1 measurement corresponding to best overall response (BOR) (e.g., 1 = 100%) (phv00504464.v1.p1)
- HARMONIZED_CONFIRMED_BOR - Confirmed best overall response (BOR) (phv00504463.v1.p1)
- HARMONIZED_OS_EVENT - Overall survival (OS) event (phv00504465.v1.p1)
- HARMONIZED_PFS_EVENT - Progression-free survival (PFS) event (phv00504461.v1.p1)
- HISTOLOGY_DETAIL - Tumor histology detail (phv00504447.v1.p1)
- HISTOLOGY_HARMONIZED - Tumor histology (phv00504446.v1.p1)
- INITIAL_STAGE - Initial tumor stage (phv00504448.v1.p1)
- INITIAL_STAGE_SUBSTAGE - Initial tumor substage (phv00504449.v1.p1)
- IS_TUMOR - Tumor status (phv00504469.v1.p1)
- PDL1_TPS - Tumor PDL1 Tumor Proportion Score (TPS) value (phv00504450.v1.p1)
- PDL1_TPS_DESCRIPTION - Tumor PDL1 Tumor Proportion Score (TPS) description (phv00504451.v1.p1)
Medications (4)
- AGENT_PD1 - PD-(L)1 agent received (phv00504457.v1.p1)
- AGENT_PD1_CATEGORY - PD-(L)1 agent category (phv00504458.v1.p1)
- PRIOR_PLATINUM - Platinum treatment prior to PD-(L)1 agent (phv00504459.v1.p1)
- PRIOR_TKI - Tyrosine kinase inhibitor (TKI) prior to PD-(L)1 agent (phv00504460.v1.p1)
Race and Ethnicity (1)
- PATIENT_RACE - Patient race (phv00504443.v1.p1)
Substance Use (2)
- PATIENT_SMOKING_PACK_YEARS_HARMONIZED - Patient smoking pack years (phv00504445.v1.p1)
- PATIENT_SMOKING_STATUS - Patient smoking status (phv00504444.v1.p1)
Other (22)
- ADVANCED_DIAGNOSIS_DATE - Date of advanced diagnosis relative to PD-(L)1 treatment start (phv00504455.v1.p1)
- ANALYTE_TYPE - Analyte Type (phv00504468.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00504425.v1.p1)
- HARMONIZED_SU2C_RNA_TUMOR_SAMPLE_ID_V2 - Tumor RNA-Seq Sample ID (phv00504439.v1.p1)
- HARMONIZED_SU2C_WES_NORMAL_SAMPLE_ID_V2 - Normal exome Sample ID (phv00504438.v1.p1)
- HARMONIZED_SU2C_WES_TUMOR_SAMPLE_ID_V2 - Tumor exome Sample ID (phv00504437.v1.p1)
- INSTITUTION - Institution (phv00504436.v1.p1)
- LINE_OF_THERAPY - Line of therapy that PD-(L)1 agent was given (phv00504456.v1.p1)
- LOCAL_ANTIBODY_CLONE - Local PDL1 antibody clone (phv00504452.v1.p1)
- PRE-TREATMENT_RNA_SAMPLE_QC - Tumor RNA-Seq sample quality (phv00504440.v1.p1)
- RNA_ALL - RNA-Seq sample available (phv00504435.v1.p1)
- RNA_COHORT_1 - RNA-Seq sample in cohort 1 (phv00504433.v1.p1)
- RNA_COHORT_2 - RNA-Seq sample in cohort 2 (phv00504434.v1.p1)
- SAMPLE_ID - Sample ID (phv00504467.v1.p1)
- SAMPLE_ID - Sample ID (phv00504428.v1.p1)
- SEQUENCING_PLATFORM - Targeted sequencing platform (phv00504454.v1.p1)
- SUBJECT_ID - Subject ID (phv00504429.v1.p1)
- SUBJECT_ID - Subject ID (phv00504424.v1.p1)
- SUBJECT_ID - Subject ID (phv00504427.v1.p1)
- WES_ALL - Exome sample available (phv00504432.v1.p1)
- WES_COHORT_1 - Exome sample in cohort 1 (phv00504430.v1.p1)
- WES_COHORT_2 - Exome sample in cohort 2 (phv00504431.v1.p1)